Joinn Laboratories(China)Co.,Ltd. (603127.SS)
CNY 17.42
(0.87%)
CNY 17.42
(0.87%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 507.09 Million CNY | -53.26% |
| 2022 | 1.22 Billion CNY | 90.65% |
| 2021 | 642.88 Million CNY | 78.03% |
| 2020 | 361.11 Million CNY | 75.18% |
| 2019 | 206.14 Million CNY | 63.59% |
| 2018 | 126.01 Million CNY | 33.8% |
| 2017 | 94.17 Million CNY | 75.88% |
| 2016 | 53.54 Million CNY | 13.95% |
| 2015 | 46.99 Million CNY | 1.42% |
| 2014 | 46.33 Million CNY | 145.69% |
| 2013 | 18.85 Million CNY | 1097.87% |
| 2012 | -1.88 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -24.62 Million CNY | -111.91% |
| 2024 Q3 | 13.01 Million CNY | -7.22% |
| 2024 Q2 | 115.85 Million CNY | 570.38% |
| 2023 Q4 | 206.76 Million CNY | -24.88% |
| 2023 FY | 572.82 Million CNY | -53.26% |
| 2023 Q1 | 214.36 Million CNY | -57.79% |
| 2023 Q2 | -97.53 Million CNY | -145.5% |
| 2023 Q3 | 275.24 Million CNY | 382.21% |
| 2022 Q3 | 70.1 Million CNY | -75.04% |
| 2022 Q2 | 280.83 Million CNY | 175.84% |
| 2022 Q1 | 101.8 Million CNY | -71.82% |
| 2022 FY | 1.22 Billion CNY | 90.65% |
| 2022 Q4 | 507.86 Million CNY | 624.41% |
| 2021 Q1 | 107.8 Million CNY | -52.61% |
| 2021 Q3 | 107.67 Million CNY | 62.99% |
| 2021 Q4 | 361.34 Million CNY | 235.58% |
| 2021 FY | 642.88 Million CNY | 78.03% |
| 2021 Q2 | 66.06 Million CNY | -38.72% |
| 2020 Q3 | 49.3 Million CNY | -20.28% |
| 2020 Q4 | 227.5 Million CNY | 361.4% |
| 2020 FY | 361.11 Million CNY | 75.18% |
| 2020 Q1 | 22.45 Million CNY | -80.4% |
| 2020 Q2 | 61.84 Million CNY | 175.39% |
| 2019 FY | 206.14 Million CNY | 63.59% |
| 2019 Q4 | 114.55 Million CNY | 161.03% |
| 2019 Q3 | 43.88 Million CNY | 36.29% |
| 2019 Q2 | 32.19 Million CNY | 107.68% |
| 2019 Q1 | 15.5 Million CNY | -73.13% |
| 2018 Q3 | 40.97 Million CNY | 141.88% |
| 2018 Q2 | 16.94 Million CNY | 63.17% |
| 2018 Q4 | 57.7 Million CNY | 40.83% |
| 2018 Q1 | 10.38 Million CNY | -81.01% |
| 2018 FY | 126.01 Million CNY | 33.8% |
| 2017 FY | 94.17 Million CNY | 75.88% |
| 2017 Q1 | -8.85 Million CNY | -119.7% |
| 2017 Q2 | 21.93 Million CNY | 347.82% |
| 2017 Q3 | 26.41 Million CNY | 20.44% |
| 2017 Q4 | 54.67 Million CNY | 106.99% |
| 2016 Q3 | 4 Million CNY | 0.0% |
| 2016 Q4 | 44.92 Million CNY | 1022.31% |
| 2016 FY | 53.54 Million CNY | 13.95% |
| 2015 FY | 46.99 Million CNY | 1.42% |
| 2014 FY | 46.33 Million CNY | 145.69% |
| 2013 FY | 18.85 Million CNY | 1097.87% |
| 2012 FY | -1.88 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 646.8 Million CNY | 21.6% |
| WuXi AppTec Co., Ltd. | 11.87 Billion CNY | 95.729% |
| Autobio Diagnostics Co., Ltd. | 1.36 Billion CNY | 62.87% |
| Thalys Medical Technology Group Inc. | -180.32 Million CNY | 381.217% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 759.76 Million CNY | 33.256% |
| Chemclin Diagnostics Co., Ltd. | 166.28 Million CNY | -204.954% |